Blog

The latest thoughts from Medicines Law & Policy partners.

The Power of TRIPS Flexibilities in Medicines Procurement

The government of Malaysia has began to roll out treatment of people infected with the hepatitis C virus (HCV).  Treatment will be a combination of...

WHO is an essential forum for debates on intellectual property and public health

Recently, Health Policy Watch reported that some European countries at the World Health Organization (WHO) Pandemic Agreement negotiations maintain that intellectual property negotiations belong...

MSF’s Access Campaign is an invaluable actor in global health; shutting it down is...

On 20 June, STAT News reported that Médecins Sans Frontières (MSF) is closing down their Access Campaign, effective as of 31 December 2024. It...

Medicines Law & Policy responds to US Health and Human Services Department request for...

On 12 December 2023 the US Health and Human Services Department (HHS) posted a notice and request for comments on “the implications of access...

The Most Common Misunderstanding about Compulsory Licensing

The belief that a country can only use compulsory licensing in cases of public health emergencies is a myth that has proven difficult to...

Wrapping up 2023 with some noteworthy medicines, law and policy developments

Welcome to our 2023 end-of-the-year blog, our annual and highly-biased run-through of notable access to medicines events of the year that is about to...

Fair Medicines Pricing requires addressing monopolies and increasing transparency in pharmaceutical markets

The 4th WHO Fair Pricing Forum took place from 6 - 8 February 2024. Ellen 't Hoen spoke at the opening plenary. Below are...

European Commission Publishes Expert Panel’s Recommendations on High Drug Prices

This month the European Commission published Innovative Payment Models for High-Cost Innovative Medicines, a report of the Expert Panel on effective ways of investing...

Never say never – Why the High Income Countries that opted-out from the Art....

To limit the ability of patent owners to charge excessive prices for patented medicines, countries can grant compulsory licences which permit others to produce...

The EU proposed Covid waivers of certain TRIPS rules are mostly meaningless

Since October 2020, discussions have been ongoing at the World Trade Organization’s Trade-Related Aspects of Intellectual Property Rights (TRIPS) Council about a waiver of...